Short divalent ethacrynic amides as pro-inhibitors of glutathione S-transferase isozyme Mu and potent sensitisers of cisplatin-resistant ovarian cancers

References

• Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014;740:364–78.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Michels J, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 2014;5:e1257.
   PubMed Web of Science ®Google Scholar
• Hanna PE, Anders MW. The mercapturic acid pathway. Crit Rev Toxicol 2019;49:819–929.
   PubMed Web of Science ®Google Scholar
• Tew KD, Monks A, Barone L, et al. Glutathione-associated enzymes in the Human Cell Lines of the National Cancer Institute Drug Screening Program. Mol Pharmacol 1996;50:149–59.
   PubMed Web of Science ®Google Scholar
• Morgan AS, Ciaccio PJ, Tew KD, Kauvar LM. Isozyme-specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chemother Pharmacol 1996;37:363–70.
   PubMed Web of Science ®Google Scholar
• Pljesa-Ercegovac M, Savic-Radojevic A, Matic M, et al. Glutathione transferases: potential targets to overcome chemoresistance in solid tumors. Int J Mol Sci 2018;19:3785–805.
   PubMed Web of Science ®Google Scholar
• Zou M, Hu X, Xu B, et al. Glutathione S‑transferase isozyme alpha 1 is predominantly involved in the cisplatin resistance of common types of solid cancer. Oncol Rep 2019;41:989–98.
   PubMed Web of Science ®Google Scholar
• Singh RR, Reindl KM. Glutathione S-transferases in cancer. Antioxidants (Basel) 2021;10:701–25.
   PubMedGoogle Scholar
• Schultz M, Dutta S, Tew KD. Inhibitors of glutathione S-transferases as therapeutic agents. Adv Drug Deliv Rev 1997;26:91–104.
   PubMed Web of Science ®Google Scholar
• Sau A, Pellizzari Tregno F, Valentino F, et al. Glutathione transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys 2010;500:116–22.
   PubMed Web of Science ®Google Scholar
• Smitherman PK, Townsend AJ, Kute TE, Morrow CS. Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. J Pharmacol Exp Ther 2004;308:260–7.
   PubMed Web of Science ®Google Scholar
• Depeille P, Cuq P, Mary S, et al. Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. Mol Pharmacol 2004;65:897–905.
   PubMed Web of Science ®Google Scholar
• Lo HW, Ali-Osman F. Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr Opin Pharmacol 2007;7:367–74.
   PubMed Web of Science ®Google Scholar
• Cho SG, Lee YH, Park HS, et al. Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1. J Biol Chem 2001;276:12749–55.
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Gupta S. The multifaceted role of glutathione S-transferases in cancer. Cancer Lett 2018;433:33–42.
   PubMed Web of Science ®Google Scholar
• Laborde E. Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. Cell Death Differ 2010;17:1373–80.
   PubMed Web of Science ®Google Scholar
• Mahajan S, Atkins WM. The chemistry and biology of inhibitors and pro-drugs targeted to glutathione S-transferases. Cell Mol Life Sci 2005;62:1221–33.
   PubMed Web of Science ®Google Scholar
• Allocati N, Masulli M, Di Ilio C, Federici L. Glutathione transferases: substrates, inhibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis 2018;7:8–22.
   PubMed Web of Science ®Google Scholar
• Stoddard EG, Killinger BJ, Nair RN, et al. Activity-based probes for isoenzyme- and site-specific functional characterization of glutathione S-transferases. J Am Chem Soc 2017;139:16032–5.
   PubMed Web of Science ®Google Scholar
• Wang CH, Wu HT, Cheng HM, et al. Inhibition of glutathione S-transferase M1 by new gabosine analogues is essential for overcoming cisplatin resistance in lung cancer cells. J Med Chem 2011;54:8574–81.
   PubMed Web of Science ®Google Scholar
• Rotili D, De Luca A, Tarantino D, et al. Synthesis and structure–activity relationship of new cytotoxic agents targeting human glutathione-S-transferases. Eur J Med Chem 2015;89:156–71.
   PubMed Web of Science ®Google Scholar
• Federici L, Lo Sterzo C, Pezzola S, et al. Structural basis for the binding of the anticancer compound 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol to human glutathione s-transferases. Cancer Res 2009;69:8025–34.
   PubMed Web of Science ®Google Scholar
• Mammen M, Choi S-K, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 1998;37:2754–94.
   PubMed Web of Science ®Google Scholar
• Clipson AJ, Bhat VT, McNae I, et al. Bivalent enzyme inhibitors discovered using dynamic covalent chemistry. Chemistry 2012;18:10562–70.
   PubMed Web of Science ®Google Scholar
• Mahajan SS, Hou L, Doneanu C, et al. Optimization of bivalent glutathione S-transferase inhibitors by combinatorial linker design. J Am Chem Soc 2006;128:8615–25.
   PubMed Web of Science ®Google Scholar
• Maeda DY, Mahajan SS, Atkins WM, Zebala JA. Bivalent inhibitors of glutathione S-transferase: the effect of spacer length on isozyme selectivity. Bioorg Med Chem Lett 2006;16:3780–3.
   PubMed Web of Science ®Google Scholar
• Lyon RP, Hill JJ, Atkins WM. Novel class of bivalent glutathione S-transferase inhibitors. Biochemistry 2003;42:10418–28.
   PubMed Web of Science ®Google Scholar
• Koehler RT, Villar HO, Bauer KE, Higgins DL. Ligand-based protein alignment and isozyme specificity of glutathione S-transferase inhibitors. Proteins: Struct Funct Genet 1997;28:202–16.
   PubMed Web of Science ®Google Scholar
• Ata A, Udenigwe CC. The discovery and application of inhibitors of glutathione S-transferase as therapeutic agents – a review. Curr Bioact Compd 2008;4:41–50.
   Google Scholar
• Ploemen JHTM, Ommen BV, Bogaards JJP, Bladeren PJV. Ethacrynic acid and its glutathione conjugate as inhibitors of glutathione S-transferases. Xenobiotica 1993;23:913–23.
   PubMed Web of Science ®Google Scholar
• Parker LJ, Italiano LC, Morton CJ, et al. Studies of glutathione transferase P1-1 bound to a platinum(IV)-based anticancer compound reveal the molecular basis of its activation. Chemistry 2011;17:7806–16.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3–25.
   Web of Science ®Google Scholar
• Lo W-J, Chiou Y-C, Hsu Y-T, et al. Enzymatic and nonenzymatic synthesis of glutathione conjugates: application to the understanding of a parasite's defense system and alternative to the discovery of potent glutathione S-transferase inhibitors. Bioconjug Chem 2007;18:109–20.
   PubMed Web of Science ®Google Scholar
• McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 2006;25:1639–48.
   PubMed Web of Science ®Google Scholar
• Yang X, Du Z, Pu J, et al. Classification of difference between inhibition constants of an inhibitor to facilitate identifying the inhibition type. J Enzyme Inhib Med Chem 2013;28:205–13.
   PubMed Web of Science ®Google Scholar
• Xu B, Tan D, Yang X, et al. Fluorometric titration assay of affinity of tight-binding nonfluorescent inhibitor of glutathione S-transferase. J Fluoresc 2015;25:1–8.
   PubMed Web of Science ®Google Scholar
• Williams JW, Morrison JF. The kinetics of reversible tight-binding inhibition. Methods Enzymol 1979;63:437–67.
   PubMedGoogle Scholar
• Caffrey PB, Frenkel GD, McAndrew KL, Marks K. A model of the development of cisplatin resistance in human small cell lung cancer xenografts. In Vivo 2016;30:745–9.
   PubMed Web of Science ®Google Scholar
• Chen B, Ke L, Xia G, et al. Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo. Int J Nanomedicine 2013;8:1867–77.
   PubMed Web of Science ®Google Scholar
• Rossmann MG, Beek CGv. Data processing. Acta Crystallogr D Biol Crystallogr 1999;55:1631–41.
   PubMedGoogle Scholar
• McCoy AJ, Grosse-Kunstleve RW, Adams PD, et al. Phaser crystallographic software. J Appl Crystallogr 2007;40:658–74.
   PubMed Web of Science ®Google Scholar
• Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004;60:2126–32.
   PubMed Web of Science ®Google Scholar
• Adams PD, Afonine PV, Bunkoczi G, Chen VB, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 2010;66:213–21.
   PubMed Web of Science ®Google Scholar
• Buist HE, van Burgsteden JA, Freidig AP, et al. New in vitro dermal absorption database and the prediction of dermal absorption under finite conditions for risk assessment purposes. Regul Toxicol Pharmacol 2010;57:200–9.
   PubMed Web of Science ®Google Scholar
• De Luca A, Parker LJ, Ang WH, et al. A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1. Proc Natl Acad Sci U S A 2019;116:13943–51.
   PubMed Web of Science ®Google Scholar
• Yan X-D, Pan L-Y, Yuan Y, et al. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J Proteome Res 2007;6:772–80.
   PubMed Web of Science ®Google Scholar
• Piaggi S, Raggi C, Corti A, et al. Glutathione transferase omega 1-1 (GSTO1-1) plays an anti-apoptotic role in cell resistance to cisplatin toxicity. Carcinogenesis 2010;31:804–11.
   PubMed Web of Science ®Google Scholar
• Pathania S, Bhatia R, Baldi A, et al. Drug metabolizing enzymes and their inhibitors' role in cancer resistance. Biomed Pharmacother 2018;105:53–65.
   PubMed Web of Science ®Google Scholar